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Abstract
Background: Mechanisms behind asthmatic cough are largely unknown. It is known that hyperosmolar challenges
provoke cough in asthmatic but not in the healthy subjects. It has been postulated that isocapnic hyperpnea of
dry air (IHDA) and hypertonic aerosols act via similar mechanisms in asthma to cause bronchoconstriction. We
investigated whether there is an association between cough response induced by IHDA and hypertonic saline (HS)
challenges.
Methods: Thirty-six asthmatic and 14 healthy subjects inhaled HS solutions with increasing osmolalities
administered via ultrasonic nebuliser until 15 cumulative coughs were recorded. The IHDA consisted of three three-
minute ventilation steps: 30%, 60% and 100% of maximal voluntary ventilation with an end-point of 30 cumulative
coughs. The challenges were performed on separate days at least 48 hours between them and within one week.
Inhaled salbutamol (400 mcg) was administered before the challenges to prevent bronchoconstriction. The cough
response was expressed as the cough-to-dose ratio (CDR) which is the total number of coughs divided by the
maximal osmolality inhaled or the maximal ventilation achieved.
Results: Cough response to IHDA correlated with the HS challenge (Rs = 0.59, p < 0.001). Cough response to IHDA
was at its strongest during the first minute after the challenge. IHDA induced more cough among asthmatic than
healthy subjects CDR being (mean ± SD) 0.464 ± 0.514 and 0.011 ± 0.024 coughs/MVV%, p < 0.001, respectively.
Salbutamol effectively prevented bronchoconstriction to both challenges.
Conclusions: Asthmatic patients are hypersensitive to the cough-provoking effect of hyperpnoea, as they are to
hypertonicity. Cough response induced by IHDA and HS correlated well suggesting similar mechanisms behind the
responses.
Introduction
Chronic cough is a common diagnostic and therapeutic
problem having prevalence up to 40% in population [1].
Cough can cause deterioration in the quality of life [2]
and its economic burden is significant [3]. It also is the
most common symptom of asthma [4]. Current thera-
pies of asthma show little clinical efficacy on cough, and
the treatment focus is on the underlying pathophysiol-
ogy of disease. A recent consensus statement by the
European Respiratory Society has highlighted the impor-
tance to further understand the mechanisms of cough
through the development of valid tests to study cough
and to identify and assess novel therapies to treat it [5].
It has been demonstrated that asthmatic cough can be
independent of bronchial obstruction. For example,
hypertonic saline provokes cough in asthmatic subjects
who are pre-treated with inhaled salbutamol that is cap-
able to block bronchoconstriction [6]. Unlike traditional
cough provocation tests by capsaicin or citric acid
[7-10], hypertonic cough provocation tests can differ-
entiate asthmatic and healthy subjects [6]. Therefore,
hypertonic challenge-provoked cough could be used in
both diagnosing and evaluating treatment response of
asthma on cough [11-13]. These findings also underline
the potential clinical relevance of hypertonic saline (HS)
challenge in investigating cough and in assessing cough
therapies. A pathological function of sensorineural appa-
ratus may be behind both asthmatic and chronic cough
[6]. However, the precise mechanism of this cough is
still unclear.
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Isocapnic hyperpnoea of dry air (IHDA) challenge is
thought to cause airway narrowing similarly to exercise
by causing airway drying and leading to an increase in
the osmolarity in the airway lining fluid [14-16]. There-
fore, hyperpnoea of dry air can be regarded as a physio-
logical stimulus. The inhalation of HS has been
postulated to cause bronchoconstriction via the same
mechanisms as exercise testing or hyperpnoea of dry air
[16]. In addition, HS induced increase in osmolarity of
the airway lining fluid is known to be a potent stimula-
tor of airway sensory nerves and thus also cough [3].
Thus, we hypothesise that the cough responses to
hypertonicity and hyperpnoea share similar mechanisms.
To further investigate this subject, we compared the
cough sensitivity to HS and IHDA in asthmatic and




Thirty-eight subjects with asthma were recruited and
entered the study from Kuopio University Hospital out-
patient clinic. All asthmatic subjects were originally
referred to this tertiary referral centre due to diagnostic
uncertainty at primary care. The diagnosis of asthma
was based on patient’s history and clinical examination
suggestive of asthma, together with objective evidence of
reversible airway obstruction in spirometry or in ambu-
latory peak expiratory flow (PEF) measurements accord-
ing to the GINA guidelines [17]. Fourteen healthy
controls were recruited from the personnel of Kuopio
University Hospital. The healthy subjects had no
respiratory symptoms; however, atopy and history of
smoking were not exclusion criteria. The exclusion cri-
teria for all the subjects were febrile respiratory tract
infection within six weeks, and post-salbutamol FEV1
less than 60% [18]. In addition, subjects with excessive
spontaneous cough (>10 coughs in response to 0.9% sal-
ine inhalation) and subjects with fall of FEV1 more than
10% during neither of inhalation challenge used, were
excluded from the study [19,20]. Thirty-six asthmatic
and fourteen healthy subjects completed the study. The
Research Ethics Committee, Hospital District of North-
ern Savo, Finland approved this study (31.10.2008 117//
2008) and all subjects provided their informed consent
for participation in the study. Subjects’ characteristics
are showed in table 1.
Non-permitted medication
The asthmatic patients were allowed to use their inhaled
corticosteroids and long-acting b-2 agonists throughout
the study but asked not to take them on the challenge
days. All cough relieving drugs, leukotriene antagonists,
and antihistamines were stopped at least three days
before the first challenge. Short-acting b-2 agonists were
withdrawn for at least 8 hours before the challenges.
Protocol
All asthmatic subjects were observed over a one-week
run-in period, during which they recorded peak expira-
tory flow (PEF) twice-daily using bronchodilator medica-
tion only when needed. Inhalation challenge with HS [6]
Table 1 Characteristics of the subjects.
Asthma Healthy control p
n 36 14
Gender (male/female) 10/26 2/12
Age 40 (18-68) 37 (21-67)
Atopy# 22 5
Smoking (mean pack years)
Current 9 (6) 0
Previous 3 (11) 0
Use of inhaled corticosteroids (ICS) 24 0
Daily dose of ICS 541 ± 391 μg -
ASA intolerance 3 0
Use of ACE inhibitors 5 0
Exhaled nitric oxide 18.4 ± 15.0 14.6 ± 6.59 0.376
FEV1 (% from predicted)
¶ 90.0 (67-122) 92.8 (78-110) 0.418
Mean daily PEF variability (%) 7.90 ± 5.75 -
Needed rescue medication doses during pre-test week 0.83 (0-4) -
CDR Hypertonic saline coughs/(mOsm/kg) 0.012 ± 0.010 0 <0.001
CDR Hyperpnoea of dry air coughs/MVV% 0.464 ± 0.514 0.011 ± 0.024 <0.001
Age, FEV1 and needed rescue medication doses mean (range).
# Atopy was assessed as ≥3 mm mean wheal diameter in the skin prick test to at least one
common aeroallergen. Daily dose of ICS, exhaled NO, mean daily PEF variability and CDR (cough-to-dose ratio) mean ± SD. ¶ Reference values are those of
Viljanen et al. [34]
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and IHDA [21] were performed on separate days with at
least 48 hours between the challenges within one week,
during the same time of the day. Skin prick tests for
common aeroallergens (Soluprick SQ®; ALK-Abello,
Hörsholm, Denmark) and measurement of exhaled nitric
oxide (eNO) (Sievers Model 280 NOA; Sievers Instru-
ments Inc., Boulder, CO, USA) were performed to all
subjects at the first visit.
Hypertonic saline challenge
An ultrasonic nebuliser (De Vilbiss Ultraneb 3000, Sun-
rise Medical Ltd, Leicester, UK) with a one-way valve
(Douglas Bag One-Way Air Valve, Harvard Apparatus,
Holliston, MA, USA) was used to deliver the saline solu-
tions. They were made by adjusting the sodium chloride
(Natrii Chloridium Ph. Eur., Tamro Ltd, Helsinki, Fin-
land) content of standard phosphate-buffered saline as
described in detail previously [6]. In the beginning of
the challenge, spirometry was performed three times
(Model M9449, Medikro Ltd, Kuopio, Finland) and the
largest FEV1 was recorded. Then the subject inhaled
four inhalations of 100 mcg salbutamol (Ventoline Evo-
haler, GlaxoSmithKline Ltd, Stockley Park West,
Uxbridge, Middlesex, UK) using a Volumatic chamber.
The spirometry was repeated 15 minutes later. There-
after the subject inhaled isotonic phosphate-buffered sal-
ine for 2 minutes using tidal breathing, and wearing a
nose clip. The coughs occurring during the inhalation
and two minutes after it were manually recorded by the
investigation nurse as described previously [22]. Subse-
quently, the subject similarly inhaled solutions with
osmolalities of 600, 900, 1200, 1500, 1800, and 2100
mOsm/kg. Oxygen saturation (SaO2) was monitored by
pulse oximetry before and after salbutamol, and after
every saline inhalation. The challenge was stopped if the
subject asked for it, 15 or more cumulative coughs had
been recorded [6], or the final solution was adminis-
tered. Finally, the spirometry was repeated.
Isocapnic hyperpnoea of dry air challenge
The challenge was performed as described earlier by
Rodwell et al. [21] with some modifications. In brief, the
subject inhaled dry compressed air (Woikoski, Varkaus,
Finland) containing 5% CO2 which prevents alkalosis
during the challenge. The apparatus used had a target
balloon (Direct Fillsingle Bag Set, Harvard Apparatus
Ltd, Edenbridge, Kent, UK) in the inspiratory line,
between the rotameter (Rotameter, Aalborg Instruments,
Kytölä, Muurame, Finland) and the mouthpiece (Dou-
glas Bag One-Way Air Valve and Mouthpiece, Harvard
Apparatus Ltd, Edenbridge, Kent, UK). A demand valve
(Aga Gas Ltd, Lidingö, Sverige) was utilised in the set-
ting of the gas flow. The subject breathed gas from the
target balloon. The subject was encouraged to keep the
size of the target balloon constant with increasing
breathing frequency and volume when the airflow to
balloon increased during the different steps of the chal-
lenge. The challenge began with measurement of base-
line FEV1. Then the subject inhaled four inhalations of
100 mcg salbutamol (Ventoline Evohaler, GlaxoSmithK-
line Ltd, Stockley Park West, Uxbridge, Middlesex, UK)
using a Volumatic chamber, and the measurement of
FEV1 was repeated after 15 minutes. The best post-sal-
butamol FEV1 was used to calculate the maximal volun-
tary ventilation (MVV), taken as 35 × post-salbutamol
FEV1. The challenge commenced breathing at 30%
MVV for three minutes. Coughs were counted manually
by the investigation nurse during the challenge and up
to 10 minutes after it [22]. Then two FEV1 measure-
ments were performed. The challenge continued with
ventilation at 60% MVV for three minutes, and suc-
ceeded with cough counting and two FEV1 measure-
ments. Finally the subject ventilated at 100% MVV for
three minutes, and cough counting and two FEV1 mea-
surements were repeated. SaO2 was monitored by pulse
oximetry in the beginning of the challenge and after
each step. The challenge was stopped if the subject
asked for it, 30 or more cumulative coughs were
recorded, or the fall in FEV1 was 10% or more com-
pared to the post-salbutamol value.
Statistical analysis
Saphiro-Wilkins test was used for normality testing due
to the sample size (n < 50). Correlation between chal-
lenge induced cough responses was determined with
Spearman’s rank correlation coefficient (Rs). Cough
response, the number of coughs as a product of the
quantity of the stimulus, was expressed as coughs-to-
dose ratio (CDR). In HS challenge CDR was calculated as
cumulative coughs/final osmolality. In IHDA challenge
CDR was determined as cumulative coughs/final MVV%.
Differences in CDR values between groups were assessed
with Mann-Whitney U-test. Normally distributed values
were compared with Student’s t-test and paired samples
t-test. Values are expressed as mean and standard devia-
tion. A p-value of <0.05 was considered to be statistically
significant. All analyses were carried out using SPSS for
Windows 15.0 (SPSS Inc.™, Chicago, USA).
Results
The cough response to IHDA correlated well to the
cough response of hypertonic aerosol among asthmatic
subjects with a relationship between coughs-to-dose
ratios Rs = 0.59, p < 0.001 (Figure 1.). In addition, the
relationship was maintained when comparing the cumu-
lative coughs at the end of the saline and IHDA chal-
lenges with a Spearman correlation coefficient of 0.46, p
= 0.01.
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Cough response to IHDA was at its strongest during
the first minute of the post-hyperventilation period,
then ceasing rapidly (Figure 2.). In some subjects cough
was prolonged following the stimulus and cough
occurred through-out the post hyperventilation period.
IHDA and HS were more potent at inducing cough in
asthmatics than in healthy subjects, p < 0.001 (Table 1).
Further, the asthmatic subjects started to cough at lower
minute ventilation than the healthy subjects (Figure 3).
The cough indices separated the asthmatic and healthy
subjects but eNO and FEV1 measurements did not
(Table 1.).
Four subjects from the asthmatic group and one
healthy subject failed to achieve their target ventilation
MVV100% during the last step of IHDA. Despite this,
three of the mentioned asthmatic subjects had cough
reaction between 29-34 coughs when minimum target
for cessation was 30 cumulative coughs, and the healthy
subject did not cough at all.
There were no statistically significant differences in
FEV1 between the two challenges in either study group.
FEV1 (expressed as % from predicted) of asthmatic sub-
jects was 89.0 ± 2.31 before the IHDA and 89.6 ± 2.25
before the HS, and 91.1 ± 2.22 and 92.8 ± 2.55 of the
healthy subjects, respectively. Accordingly, FEV1 after
IHDA and HS was 92.4 ± 2.08 and 92.7 ±2.13 among
asthmatic, and 96.7 ± 2.28 and 97.6 ± 2.69 among
healthy subjects. Post-salbutamol FEV1 did not differ
significantly from the FEV1 at the end of challenge in
either of the tests nor in either of the groups: Salbuta-
mol prevented a fall of FEV1 among asthmatic subjects
with the reductions in FEV1 only a mean (range) 0.32%
(-3.8% - +5.1%) after HS and -0.9% (-6.7% - +9.3%) after
IHDA. There was no clinically significant reduction in
SaO2 in association to hyperpnoea with the saturation
being 97.4 ± 0.2% before and 97.1 ± 0.2% after the chal-
lenge. The same was observed for HS with the mean
SaO2 before and after the challenge being 96.9 ± 0.2%
and 97.1 ± 0.3%. However, two asthmatic subjects had
decrease >4% in SaO2 during coughing in the end of HS
challenge and this was not related to any change in
FEV1.
Discussion
The results of this study show that asthma patients with
cough response to HS also have similar cough response
to IHDA. In addition, the profile of the cough response
following IHDA is similar to that of HS in our previous
study [6]. The IHDA induced cough is at its strongest
during the first minute after the challenge followed by
rapid decline in the response. These findings support
our hypothesis that the mechanism behind the cough
response is the same in these challenges.
It has been proposed previously that IHDA causes
water loss from the airways similarly to exercise chal-
lenge [14]. This leads to changes in osmolarity of the
airway lining fluid and probably also in the epithelial
cell. It has been further hypothesised that this is the
main mechanism behind the bronchial obstruction in
hyperpnoea- and exercise-induced asthma [23]. Several
reports support this hypothesis. The results of Smith et
al. have demonstrated that bronchial obstruction pro-
voked by inhalation of 4.5% saline correlated to that of
IHDA in both intensity and onset of action [15]. The
similarity of the airway responses to exercise and
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Figure 1 Coughs-to-dose ratio (CDR) of isocapnic hyperpnea of
dry air challenge in relation to CDR of hypertonic saline
inhalation challenge of asthmatic subjects (n = 30).





















Figure 2 Number of provoked coughs (means and standard
errors) at each stage of all isocapnic hyperpnea of dry air
challenges of asthmatic subjects (n = 30).
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[24] further support the concept that these indirect
challenges initiate same pathophysiological responses in
the airways to cause bronchoconstriction.
In this study, in addition to the cough response corre-
lating strongly between HS and IHDA challenges, we
found that the cough responsiveness was at its highest
during the first minute following the IHDA, mimicking
previous findings after inhalation of HS [6]. The peak of
the cough response appeared earlier than the largest
decrease of FEV1 reported in the earlier studies after
either IHDA or HS challenge where the maximum air-
way response can be expected five minutes after the
withdrawal of the stimulus [15,25]. These findings
together suggest that mechanism behind the evoked
cough response after HS and IHDA challenges is likely
to be similar. In the contrast to the bronchoconstrictive
response to hypertonicity and hyperpnoea, the cough
response to these stimuli is probably not associated with
mast cell derived mediator release [26]. The putative
role of mast cell in the bronchoconstrictive response to
hypertonicity and hyperpnoea is highlighted by the
strong inhibitory effects of mast-cell stabilising agents
on this response [11,27,28]. However, the present and
our previous studies demonstrate that these drugs, i.e.
salbutamol and nedocromil are without effect on the
cough response on these stimuli [6,11].
The appearance of the cough response to IHDA and
hypertonicity with delay, i.e., after the challenges, has
previously been considered as a proof for an indirect sti-
mulation of the cough receptors via a mediator release
[6]. However, Lavorini et al. have recently reported that
both exercise and isocapnic hyperpnoea of dry air can
down regulate the sensitivity of the cough reflex [29].
This finding is important and may actually explain the
delayed cough response to IHDA and hypertonicity
shown in the present and our previous study [6].
Previous studies utilising capsaicin in cough induction
have not been able to show any clinical use of it in diag-
nosing asthma or in evaluating treatment response of
asthmatic cough [8,9,30,31]. In addition, capsaicin chal-
lenge does not seem to have any correlation to mannitol
in the assessment of chronic cough [32]. Capsaicin as
well as citric and tartaric acids are known to activate
airway sensory nerves via the stimulation of the type 1
vanilloid receptor (TRPV 1). In contrast, HS, which is a
robust activator of airway sensory nerves, acts indepen-
dently of TRPV1 [3]. The present results suggest that
IHDA may act via the same mechanism as HS in cough
induction. Mannitol, another hyperosmolar stimulus,
also may utilise the same pathway [33]. However, the
recognition of the precise sensory neural mechanism
responsible for the HS and IHDA induced cough is
needed.
This paper presents a new type of physiological cough
provocation test, IHDA after salbutamol pre-treatment.
One could criticise the use of different end-points in the
challenges. The end-point of fifteen coughs for saline
challenge had been previously determined [6]. However,
the end-point of thirty coughs for IHDA challenge was
an estimation. Determination of an end point requires a
repeatability study. So far, repeatability study of IHDA
as an cough challenge has not been performed. In
future, an accurate end-point should be evaluated also
for IHDA induced cough. There were no clinically sig-
nificant decreases in FEV1 or oxygen saturation levels
during either of the challenges utilised in this study. At
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Figure 3 The cumulative number of coughs in relation to minute ventilation evoked by isocapnic hyperpnea of dry air challenge in
each (a) healthy (n = 10) and (b) asthmatic (n = 30) subject. The horizontal lines at or below zero indicate subjects who did not cough at
all.
Purokivi et al. Cough 2011, 7:8
http://www.coughjournal.com/content/7/1/8
Page 5 of 7
the present, both HS and IHDA seem to be physiologi-
cal and safe challenges for cough research. Though chal-
lenge induced cough may be uncomfortable to the
patient, it is safe to perform as no adverse events have
been observed.
In conclusion, cough response to hypertonic saline
compares well to the cough sensitivity to the real life
cough stimulant, hyperpnoea of dry air. This report sug-
gests that safety and practicality of HS and IHDA
induced cough response could be utilised in investigat-
ing mechanisms of cough.
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